share_log

BTIG Initiates Coverage On MariMed With Buy Rating, Announces Price Target of $0.85

BTIG Initiates Coverage On MariMed With Buy Rating, Announces Price Target of $0.85

BTIG以買入評級啓動對MariMed的報道,宣佈目標股價爲0.85美元
Benzinga Real-time News ·  2022/10/28 09:18

BTIG analyst Jonathan Decourcey initiates coverage on MariMed (OTC:MRMD) with a Buy rating and announces Price Target of $0.85.

BTIG分析師喬納森·德庫西開始對MariMed(場外交易代碼:MRMD)進行報道,評級爲買入,並宣佈目標股價爲0.85美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論